Skip to main content

Trivaris Side Effects

Generic name: triamcinolone ophthalmic

Medically reviewed by Drugs.com. Last updated on Feb 18, 2024.

Note: This document contains side effect information about triamcinolone ophthalmic. Some dosage forms listed on this page may not apply to the brand name Trivaris.

Applies to triamcinolone ophthalmic: intraocular suspension.

Serious side effects of Trivaris

Along with its needed effects, triamcinolone ophthalmic (the active ingredient contained in Trivaris) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking triamcinolone ophthalmic:

More common

Less common

Incidence not known

Other side effects of Trivaris

Some side effects of triamcinolone ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to triamcinolone ophthalmic: intraocular suspension, intravitreal suspension.

General

The most commonly reported side effects were elevated intraocular pressure and cataract progression.[Ref]

Ocular

Frequency not reported: Endophthalmitis (infectious and non-infectious), hypopyon, injection site reactions (described as blurring and transient discomfort), glaucoma, vitreous floaters, detachment of retinal pigment epithelium, optic disc vascular disorder, eye inflammation, conjunctival hemorrhage, visual acuity reduced, exophthalmos[Ref]

Hypersensitivity

Frequency not reported: Anaphylactoid reaction, anaphylaxis, angioedema[Ref]

Cardiovascular

Frequency not reported: Elevation in blood pressure, bradycardia, cardiac arrest, cardiac arrhythmia, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis[Ref]

Dermatologic

Frequency not reported: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scalp, edema, facial erythema, hyper or hypopigmentation, increased sweating, petechiae, ecchymosis, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria[Ref]

Endocrine

Frequency not reported: Alteration in glucose tolerance, abnormal fat deposits, decreased carbohydrate tolerance, development of Cushingoid state, hirsutism, manifestations of latent diabetes mellitus and increased requirements for insulin or oral hypoglycemic agents in diabetics, menstrual irregularities, moon facies, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery or illness), suppression of growth in children[Ref]

Gastrointestinal

Frequency not reported: Abdominal distention, hiccups, malaise, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, ulcerative esophagitis[Ref]

Metabolic

Frequency not reported: Fluid retention, increased appetite, weight gain, potassium loss, hypokalemic alkalosis, negative nitrogen balance due to protein catabolism[Ref]

Musculoskeletal

Frequency not reported: Aseptic necrosis of femoral and humeral heads, Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture, vertebral compression fractures[Ref]

Nervous system

Frequency not reported: Arachnoiditis, convulsions, headache, increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually following discontinuation of treatment, insomnia, meningitis, neuritis, neuropathy, paraparesis/paraplegia, paresthesia, sensory disturbances, vertigo[Ref]

Genitourinary

Postmarketing reports: Alteration in motility and number of spermatozoa[Ref]

Hepatic

Frequency not reported: Elevation in serum liver enzymes levels (usually reversible upon discontinuation), hepatomegaly[Ref]

Other

Frequency not reported: Impaired wound healing[Ref]

Psychiatric

Frequency not reported: Behavioral and mood changes, depression, emotional instability, euphoria[Ref]

Respiratory

Frequency not reported: Pulmonary edema[Ref]

References

1. Product Information. Triesence (triamcinolone ophthalmic). Alcon Laboratories Inc. 2007.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.